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Background. Human exposure to POPs (e.g. Dioxins, PCBs,...) is of concern. During 
biomonitoring campaign, individual bodyburden is estimated by measurements of serum 
levels. Depending on the analytes, up to 50 mL of serum are required from patients. This 
is negatively perceived and excludes young infants/elderlies from being sampled. 
Objectives. In the quest for an easy to use and non-invasive sampling method, we have 
been investigating alternative microsampling approaches to reduce the level of 
invasiveness while maintaining the requested sensitivity. Several gas chromatographic (GC) 
and mass spectrometric (MS) methods have been studied to measure at sub picogram (pg) 
LOQ level. The aim was to keep sample volumes below 50 μL. 
Methods. Dried-blood spots (DBS), processed using micro-extraction by packed sorbent 
(MEPS) were analyzed by cryogenic zone compression (CZC) coupled to negative chemical 
ionization (NCI), and high resolution time-of-flight MS (HRTOFMS). We also developed a 
very sensitive method based on the use of volumetric absorptive microsampling (VAMS) 
and GC coupled to triple quadrupole tandem in-space MS (GC-QQQMS/MS) for 
measurements. CZC measurements were also implemented using a sector MS instrument to 
take advantage of the most sensitive MS analyzer operating in selected ion monitoring 
(SIM) at high acquisition rates. Isotope dilution (ID) was used in all approaches. 
Results. CZC applied to GC-NCI-IDHRTOFMS was used for the screening of markers of 
exposure (PCB-153, DDE) in 20 μL serum samples. The use of MEPS was automated with 
success and required only 500 μL of solvent for extraction. The non-scanning HRTOFMS 
analyzer makes analyses of other unknown and/or emerging compounds possible in the 
future. VAMS and GC-IDQQQMS/MS allowed to measure levels of 24 OCPs and 6 non dioxin- 
like PCBs (NDL-PCBs) in 40 μL whole blood. The sample preparation, involving micro-scale 
solid phase extraction (SPE), used 2 mL of solvent per sample. We reported analyte levels 
for a series of real human samples. 
Conclusion. These minimally-invasive methods offer an alternative to conventional 
approaches in order to easily gather data from people in remote area, from young infants, 
or for purposes where blood volumes are restricted to a minimum. 
 
 
